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WE HAVE reported encouraging clinical trials with a 
new ImmunosuppreSSive agent called FK 506. 1- 3 
which is a macrolide antibiotic produced by the fungus 
Streptomyces Dsukubaensis:~ The molecular structure of 
FK 506 is unrelated to cyclosporine (CyA,. and the two 
drugs have different cVlosolic binding sues. RK~ However. 
'10th drugs inhibit vKf~ mphocyte activation. In part by 
~uppressing the synthe~ls and expression of the cytokine 
interleukin 2.4.1·8 Both drugs appear to be potent suppres-
sors of T-cell function. although FK 506 accomplishes 
equal immunosuppression at levels 100Himes less than that 
of CyA. The first clinical use of FK 506 was preceded by 
extensive in vitro and in vivo studies. 
In the first human studies with FK 506. this agent was 
used as a .. rescue" drug. in that patients with complica-
tions and failure of CyA were converted to FK 506. The 
results of this studv showed a marked ability to reverse 
ongoing rejection. even 10 cases where chronic changes 
were observed. I .. 1 ThiS served as the rationale to begin 
Inals of FK 506. with low-dose sterOids. as the initial 
rnmunosuppressive regimen to treat liver transplant pa-
lIents. This Phase I pnmary treatment study was begun on 
.\ugust I n. I t)X9. These were the first human patients to be 
given FK 506. along With low-dose ~terlidsK as their 
pnmary Immunosuppressive baseline regimen. FK 506 
was shown to be remarkably potent and successful as 
primary immunosuppression in liver transplantation. De-
tailed analYSIS of the results of the FK 506 primary treated 
liver allograft reCIpient group has been reported. There 
were 110 adult patients entered at the Presbyterian Uni-
versity Hospital up to February 4. 1990. In comparison. a 
total of 320 consecutive liver transplant patients treated 
with CyA In 1988 were used as a histoncal control group. 
~inety-nine 190.0%) of the 110 FK 506 primanly treated 
liver transplant patients were alive at 12 months following 
Iransplantatton. with a corresponding graft survival of 
X3%. These Imego,"g results were stattstically better than 
that of the CyA-treated control group. 
The next phase of FK 506 study. which sequentially 
followed the initial pilot study. was to perfonn a random-
ized trial to compare FK 506 with Cy A. The deSign of this 
study was to use FK 506 and Cy A. along with steroids. in 
a randomized fashion In patients undergomg primary liver 
transplantation. Patients with significant preoperative risk 
factors were excluded from randomization because of a high 
risk of development of posttransplant medical problems. 
The primary endpoint of the randomized study was the 
failure of a defined treatment regimen to prevent and 
control rejection. Our initial presumption was that graft 
and pattent SUrvival would be essentially the same between 
the two treatment groups because patient outcome after 
treatment failure was individualized to each patient as 
deemed necessary by the investigators. Therefore both 
patient and graft survival were considered only as a 
secondary endpoint. The degree offreedom from rejection 
was considered a parameter associated with the primary 
endpoint. and this figure was also analyzed between the 
two groups. Freedom from rejection and requirement of 
supplemental immunosuppression were chosen as primary 
endpoints to provide sufficient objective eVidence to re-
solve key questions. while preserving. as much as possi-
ble. the ethical responsibility to treat patients in accor-
dance with the best practice. as currently understood. 
MATERIALS AND METHODS 
InclUSion and ExclUSion Critena 
All male and female pallenls 16 to 60 years of age who were 
referred for liver transplantallon were conSidered as pOlenllal 
..:andldates for randomizallon. with appropnate Informed consent. 
The following pallents were excluded from randomization If they 
met any of the follOWing cntena: 
I. HepalltlS B ViruS camers 
~K Patients wit h cancer 
3. Patients undergOing multiple organ transplantation 
4. Patients with prc-exisling renal failure 
5. Active infection 
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6. Stage 4 coma. defined as unconscious and ventilator depen-
dent 
7. Clinically significant hean or lung disease 
8. Previous reconstructive or bypass procedures of the liver 
9. Technically unsatisfactory operations with poor immediate 
liver function. 
Details of Randomization 
The patients were randomized 4 hours after full revascularization. 
shonly before the first dosage of FK 506 or CyA was adminis-
tered. The surgeons did not know the randomization status during 
the donor search. operation. or early intraoperative phase. Treat-
ment assignment was determined by a computer program imple-
menting the block randomization technique. to assure that the 
treatment groups remained reasonably balanced. A sealed enve-
lope method was implemented. Each envelope contained a single 
treatment assignment. 
Immunosuppressive Therapy 
FK 506. An intravenous dose of 0.10 mg/kg of FK 506 was 
admimstered over a period of ~4 hours. beglnmng4 hours after the 
new liver was revascularized. and conllnued daily unlll pallents 
were able to take oral medicallons. At this time. 0.15 mgtkg was 
given orally every 12 hours. Provisions to either increase or 
reduce the oral dose were made. if adequate levels of FK 506 were 
not maintained. as judged by the clinical course and FK 506 blood 
levels. Twelve·hour levels were monitored and levels of 1.0 
nglmL-5.0 ng/mL maintained. FK 506 doses were increased if 
there was evidence of rejecllon and there was Iiule or no associ-
ated toxicity at the present dose. and if FK 506 oral trough levels 
were not above 5 ngtmL. Trough plasma levels of FK 506 were 
measured by a monoclonal enn'me Immunoassay technique." 
Cydosporm~ IC.vAI. An intravenous dose of 4 mg/kg of CyA 
was administered over a penod of ~4 hours. beginning 4 hours 
after the new liver was revasculanzed. unlll pallents were able to 
take oral medications. at which lime Cy A doses of 8 mg/kg were 
given orally every I:! hours. Again. provIsions to Increase the oral 
Jose were made if adequate levels of Cv A were not maintained 
and to reduce the dose If indicated bv (\·A whole blood levels 
and10r eyA tOXICity. TJx CyA levels ~f 800 to 1500 ng/mL were 
mamtamed on I ~-hour trough levels. Allowance for downward 
TdX CyA trough levels were made dunngthe 2nd postoperallve 
month to tJ(JG..SOO ngtmL. Cy A doses were increased if there was 
evidence of rejection and there was Iiule or no associated toxicltv 
at the present dose. and if TdX CyA blood levels did not ns~ 
above the 1500 ng/mL range. 
Surmd qft~rapKDvK For both treatment groups. a single intraop-
erallve dose of I g of intravenous methylprednisolone was given 
followed by a daily dose of ~l mg/d unlll oral therapy was staned. 
:\ dose of 10 mg/d of prednisone was given once oral medicallons 
were staned. A dose reducllon to 10 mg/day was allowed. with 
hoth FK p~ and eyA-treated pallenls. at 1 weeks if there had 
heen no evtdence of clinical or histopathologic reJecllon. A funher 
Jose reducllon to 5 mg/d was allowed at the end of the month If 
there had been no evtdence of reJection. Pallents were taken olf 
,terolds If there was no eVidence of reJecllon. 
Supplemental ImmunosuppressIOn 
In the event of liver allograft dysfuncllon. a liver biOpsy was 
<lbtalDed and evaluated In a blinded manner by the liver transplant 
patholOgists. without knowledge of the treatment group. One 
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gram of intravenous methylprednisolone was given for biopsv. 
proven rejection. If no response was obtained within 48 hours. ~Fr 
if worsening of biochemical parameters or clinical deterioration 
occurred. then the endpoint had been reached and this event \,;" 
recorded and treatment was individualized. If a patient \', 
randomized to receive CyA. then failure of supplemental stern: 
was treated either by conversion of the baseline immunosupprc, 
sion from CyA to FK 506. or by a 5-day course of OKTJ (IH 
mgtdl. or funher augmentation of steroids. If a patient was 
randomized to receive FK 506. then the steroid-resistant rejection 
episode was treated by a 5-day course of OKTJ. or by augmen. 
tation of steroids. Response was defined as the return of the 
abnormal parameter to the baseline value. 
Definition of Liver Rejection 
The diagnosis of liver allograft rejection was based on the positive 
histologic findings but also required preliminary negative stUdies 
as follows: liver ultrasound with intact liver vascularization. and 
non-dilated bile ducts. A cholangiogram and an aneriogram were 
performed if the ultrasound findings were equivocal. 
Clinical findings that suggest rejection were based on clime; 
biochemical. and pathologic 'o features. These features inclu~k 
the following: 
Clinical: fever >38.3°C. without a source of infection: dimin-
ished bile output or altered bile character if a T·tube was present: 
and/or presence of increased ascites. 
Bioch~mica/: elevation in total bilirubin. SGOT. SGPT. alkaline 
phosphatase andlor gamma-glutamyl transpeptldase 1.5 times the 
larger value of either the lowest value I week prior to onset of liver 
dysfunction. or over the upper limit of normal. 
Path%llicCI/: 
(a) a predominantly mononuclear ponaltract infiltrate in which 
the inllammatory IDfiltrate consisted of .50% to 60% mono· 
nuclear cells intermixed with polymorphonuclear cells and 
eosinophils: 
(b) charactenstic localization of the inllammatory cells around 
and beneath the swollen endothelium of ponal caplllllnl' 
and small veins. with infiltration and damage of the eplII' 
Iium of small bile ductules: 
IC) absence of the foliowlDll histologiC tindings: signlficanl 
panlobular IDHammatlon: piecemeal necrosIs: cholanglollir 
proliferation: disarray. With balioonlDg and spotty indivld· 
ual hepatocyte necrosis: and promlDent Iymphohistiocytll: 
infiltrallon of the hepatic lobule. with inflammatory cell 
destrucllon of hepatocytes. 
StatistICal AnalYSIS 
Comparison of the two treatment arms. In regard to patient 
,urvival. used Kaplan Meier estimates. tir.ut survival and free· 
dom from rejection were treated similarly. Pallents who died with 
an apparently (uncllontntr lrafl were treated as graft failure so a, 
to obViate the need to decide the cause of death in each ca,c. 
Stallstlcal compansons of both graft and patient SUrvivalS \\«.,.-
made utilizing the Pete-Prentice method. 
Adjustments for prognostic factors. USIDIl proponional hazaru-
modeling. was not utilized in this analysis. In this randomlzcd 
Inal. mOSI adverse prognostic factors affecting liver transplanta· 
tion. were eliminated by the exclusion cnteria. These patients 
were excluded from randomization because of a high risk of 
development of posttnnsplant medical problems that may dect 
graft and palaenl sumval. 
, .. -
-------- ---------
FK 506 VS CyA 
Table 1. Patient Characteristics 
FK 506 
Number of patients 41 
\1edian age (y) 42 
"1edl8O follow-up (d) 343 
',1aJelfemale 21/20 
Original liver disease 
Biliary cirrhosIS 10 
Hepatocellular 31 
Number of deaths 3 





Number of retranspl8OtallOns 2 



























Eighty-one patients were entered into randomization dur-
109 the period of February 17. 1990. to August 31. 1990. 
Follow-up of all patients was to May 7. 1991. Forty-one 
patients were randomized to receive FK 506 following 
liver transplantation. while 40 patients were randomized to 
the Cy A group. Table I shows the clinical data of patients 
randomized to the CyA and FK 506 treatment groups. The 
median follow-up for both groups was the same. 346 days 
for CyA and 343 days for FK 506. The median age for both 
groups was 42 years of age. The male/female rallO was 
~lightly ~kewed in the Cy A group t27 males. 13 females). 
whereas the FK 506 group was about equalt21 males. 20 
femaiesl. The incidence of the ongmal liver diseases. with 
respect to biliary Cirrhosis vs hepatocellular disease. was 
~fmllar 10 both groups. Biliary CirrhOSIS accounted for 10 
pallents 10 the FK 506 group and 7 patIents 10 the CyA 
group. Hepatocellular disease accounted for 31 patients in 
the FK 506 group and 33 patienls in the CyA group. 
Patient and Graft Survrval 
Patient death was defined as pallent death tfrom any 
cause I. while graft failure was defined as pallent death or 
graft replacement. Fig I depicts the patient survival curves 
for the 41 FK 506 and 40 eyA randomized patients. The 
3-month patient survival for the two groups was 100% for 
the FK 506 pauents and 90% for the CyA group. The 
()..month figures for patient SUrvIVal were 95Cf and 85%. 
respectively (p = .400. NS). The 12-monlh patient survival 
for FK 506 and CyA groups was 93% and 111%. respec-
lively (p = Kf!~K NS). Fig 2 illustrates the corresponding 
graft survival curves for these patients. The 3-month graft 
'Urvlval for the two groups was 95% for the FK 506 vs 113% 
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Fig 1. Companson of the pallent survIVal curves for all FK 506· 
and CyA-randomlzed patients. 
were 93% and 78%. whereas the 12-month graft survival 
was 90% and 70%. respectively. 
The causes of patient and gral't losses are also listed in 
Table I. In the FK 506 group. three patients died. two from 
sepsis (one bacterial. one opportunistic fungal). and one 
from an iatrogenic cause (hemothorax). In the CyA group, 
seven patients died. One patient died as a sequela of 
rejection. developing hemodynamic instability before re-
transplantation could be performed. Two patients died 
from bacterial sepsIs. following retransplantatlon for vas-
cular thrombosis preceded by rejection. One death was 
attributed to disseminated posttransplant Iymphoprolifer-
ative disease (PTLD) after conversion to FK 506 following 
rejection. One death was attributable to complications 
related to respiratory arrest following retransplantallon for 
preservation mjury. One patient died because of over-
whelming sepsIs related to neutropenia followmg treat-
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Fig 3. The percentage of patients in each group who remained 
reJection free IS pJotted against the numoer of months posttrans· 
plant for both eyA and FK 506 pallents. 
to FK 506. One other patient died as a result of Pneumo· 
(\·.\'tIS nmnii infection. 15 months follOWing transplantation. 
Two patients in the FK 506 limb required retransplan-
[ation. one from cytomegalovirus infection and the other 
from a combination of rejection and ischemic injury. Seven 
of the original Cy A-treated liver allografts were retrans-
planted. Three grafts were lost to rejection or complica-
tions of rejection and were retransplanted. Two grafts 
~utfered severe Ischemic injury and required retransplan-
tation. One graft was retransplanted because of persistent 
hemolysis related to Rh incompatlbilitv. One liver was lost 
at 350 days hecause of hepatic artery thrombosIs and 
accelerated graft atherosclerosIs. 
InCidence of Relectlon 
One measure of the etfectlveness of a baseline immuno-
,uppresslve regimen IS the reJection-free rate follOWing 
transplantation. Because liver allogmft rejection was 
,tnctlv defined biochemlcallv. histologically. and/Or clim-
-:allv. [hiS parameter wa, a 'Imple. llh,ectlve endpomt. :\ 
tlHal of ~even Cy A patients were excluded from this 
.lnalysis. kaving a total of 33 liver allografts that could be 
l!valuated for development of rCJectlon. Two patients in 
the Cy A group were retransplanted hecause of persistent 
rreservatlon injury: one patient requested removal from 
CyA and conversion to FK 506: and one pallent was 
retransplanted because of Rh incompatlbllitv with he mol-
D~fpK Three additional grafts were convened from CyA to 
rK 50ft early in the posttransplant penod because of an 
dement of ischemic inJurY. No patient In the FK 506 group 
was excluded in this analvsls. 
Fig 3 ,hows the percentage of pallenlS in each group 
who remained rejectIOn free. The major inCidence of 
rejection episodes 10 both groups occurred wllhin the first 
10 days. In the FK 506 group. the first episode of rejection 
,'ccurred at a mean day of 11.5 follOWing transplantation. 
In contrast. the first rejection episode occurred a mean of 
4.9 days followmg transplantation 10 the C~DA group IP < 
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Pahent dropout from CyA limb 








'Includes Inree pabent5 woo were convened 10 FK 506 al lIIe lime 01 
retranspianlatlOn lor relectlon. 
.(05). In addition. a statistically significant larger number 
of patients in the FK 506 group remained free of rejection 
during the period of follow-up (p < .025), At I month. the 
rejection-free rate for the FK 506 patients was 61.0%. 
while the CyA value was 18.1% (P < .0(1). There were 
few late rejections. three in the FK 506 group over the next 
II months. while two additional late rejections were seen 
in the Cy A group. 
Supplementation of Immunosuppression 
Augmented immunosuppression was used when the stan-
dard immunosuppressive regimen was unable to control 
rejection. The initial treatment was a bolus of methylpred-
nisolone to reverse an episode of liver allograft rejection. 
When the augmented sterOid dose was unable to reverse 
the reJection. subsequent treatment was individualized in 
all instances. FK 506 crossover. administration of a steroid 
recycle. or administration of OKT3 were options in those 
patients on CyA. On the other hand. pallents on FK 50n 
were given OKT3 or additional steroids. The mean number 
of stcroid boluses given per patient dunng the first 90 day, 
'\'as 0.50 for the FK S06 group and O. if\} for the Cy A grollr 
tP < .tlll. 
In the FK S06 group. a total ot eIght patients tX/41. 
19.5':'f) reqUired OKT3. Only one patient related to failure 
llf FK 506 reqUired retransplantatlon with OKT3. This 
patient also had evidence of persistent preservation Injury. 
In the CyA group. a total of 11 patients 112140. 30%) 
reqUired OKT3. A total of 29140 l\A-trcated patients were 
converted to FK 506. The reasons for Cy A conversion to 
FK 506 are shown in Table 2. Of the 11 Cy A patients who 
reqUired OKT3 related to ongomg rejectIOn. a total of eight 
patients were convened to FK 506 after a course of OKT3. 
Twelve additional patients were convened to FK 506 
follOWing failure of a course of augmented sterOids. with-
out utiliZing OKT3. Two other patients were converted to 
FK SOft as primary therapy for reJection. one because ot 
Jifficultles in the control of diabetes. and the other patient 
who refused additional sterOids. Five Cy A-treated grafts 
were convened to FK 506 because of persistent ischemIC 
..:hanges in the Immediate posttransplant penod. and one 
hecause of dropout from the Cy A group related to patient 
request. Of the five grafts convened to FK 506 for ische-
FK 506 VS CvA 
Table 3. Serum Creatinine in CyA and FK 506 
Randomized Patients 
CR 
Post'()L TX Month irTlgldL) 
CyA--Notconverted 
1 1.53::: 0.39 
2 1.59::: 0.39 
3 1.66 ::: 0.41 
4 1.71 ::: 0.32 
6 1.68::: 0.44 
CyA-FK 506 rescue 
1 1.71 ::: 1.17 
2 1.90 ::: 0.51 
3 2.06:!: 0.84 
4 1.62:!: 0.67 
6 1.61 ::: 0.69 
FK 506 
1 1.54::: 0.62 
2 1.70 :!: 0.61 
3 1 71 :!: 0.70 
4 1 61 :!: 0.41 
6 175 :!: 0.71 
mic injury. two required retransplantation. while three 
grafts improved. One patient was given a course of ste-
roids. OKT3. and finally converted to FK 506. because of 
an Rh incompatibilitv. which eventually required retrans-
plantation. 
Renal Function 
Renal function in both groups of pallents was assessed by 
the reqUiremenr for hemodialysis and the serum creatinine 
at monthlv determlnattons. The requirement for hemodi-
alYSIS. as a preterminal event. was seen In one patient in 
the FK 50ft group. and in three patients In the CvA group. 
HemodIalysIs was initiated in SIX Cy A patlenls whIle stili 
(In LvA. \vhereas three other CyA pallents reqUired hemo-
thalv~ls Junng the penod of converSIon to FK 50ft. In the 
FK S(1tt randomized group. four pallcnts were placed on 
hemodlalvsls dUring the posttransplant period. The com-
parative mCldence for hemodialysIs requirement between 
the FK 506 and CyA groups texcluding terminal hemodi-
~lfyslsl was 10% and 21.6%. respectively. Long-term he-
modialYSIS tafter 3 months' posttransplanll was only reo 
quired In one patient m each group. 
Table 3 show~ the mean serum creatinine of patients 
with functioning kidneys. each month follOWing transplan-
tation. for both FK 506 and C~A patients. In addition. 
those pattents who were converted to FK 506 from the 
Cv A group have creatinine levels shown separately. Dur-
iOg the tirst 4 monrhs there was little appreciable difference 
In the serum creallnlne for the three groups with function-
ing kidneys. 
Intectlous Disease and Malignant Complications 
InCIdence of opportunistic infections was analYZed for 
each pattent. wnh appropnate investigations when chni-
2981 
callv indicated. and with routine surveillance cultures for 
vi~1 infections. The incidence of opportumstic infections 
was essentiallv the same for both groups. Patients who 
were randomi~ed to CyA had a 21.5% incidence of cyto-
megalovirus infections (CMY). This compared to 22.0% 
incidence for patients on FK 506. In the 13 CyA patients 
who were not switched to FK 506. the incidence of CMY 
was 23% (3/13). and only one of the three patients received 
OKT3. In the FK 506 patients. three of the total nine cases 
of CMY occurred in patients who had preVIously received 
OKT3. 
Two cases of miliary tuberculosis were seen in patients 
originally randomized to Cy A but switched to FK 506 after 
having received augmented steroids and OKT3. Both 
patients responded to triple drug therapy with rifampin. 
isoniazid. and ethambutol. Single cases of recurrent hep-
atitis C virus. acquired hepatitis B. and herpes simplex 
virus were seen in the Cy A-treated group. In addition. 
three cases of severe symptomatic candidal infections 
were seen in this group. Two cases of IYrLD were seen in 
the CyA randomized patients. One occurred in a patient 
who was converted to FK 506 for steroid-resistant rejec-
tion. whereas the other occurred in a patient who was still 
on CyA. 
In the FK 506-treated group. there were two cases of 
recurrent hepatitis C virus and one case of acute mononu-
cleosis due to Epstein-Barr virus. One fatal case of dis-
~eminated candida was seen in a patient who did not 
require any augmented immunosuppression while on FK 
506 therapy. 
Other Parameters 
/lvfJ('f(('n.fion. The severity of hypertensIon was as-
.,essed by the need for antihypertensive medicallons fol-
lowing transplantation. The inCidence of hvpertension in 
the overall Cy A randomized group was 52. 'Y''r v~ 26.9% for 
the FK 506-treated group .P < .01 I. at -' months' post-
transplant. This figure did not change appreclablv over the 
follow-up period: at the current follow-up penod. the 
corresponding hypertensive incidence was ~·u% for CyA 
and 33.3% for FK 506. The incidence of hypenension in 
the 14 patients who were on CyA at the 3-month posttrans-
plant period was 64.2%. The current figure .at the time of 
analysis} was n.7% for those patients sll/l on CyA. while 
the conversion group had an incidence Similar to those 
given FK 506 from the start 06.4%1. 
Induction o(Diabet('J Me/lifllJ In Nond/(/beli(' PatientJ. 
The need for insulin therapy was evaluated bv determining 
those patients who reqUIred insulin at the -'-month period 
follOWing transplantation. No statistically ~ggntficant dif-
ferences eXIsted between the two groups 01 patients. In the 
FK 506 group. 17% of the patients reqUired Insulin at 3 
months' posltransplant. For the CyA group. 17.5% of the 
patients required insulin at the same ttme POlnl. 
Prednisone Requiremenu. The amount 01 malnlenance 
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Fig 4. The mean doses of prednisone per day is charted agamst 
the time posttransplant for CyA and FK 506 groups. For the CyA 
group. two curves are shown. one bemg for those patients who still 
remain on CyA vs the group that was converted to FK 506. The 
percentage of patients in each group who are ott all steroids IS 
shown at each time pomt. 
mined at monthly intervals. As shown In Fig 4. the mean 
maintenance dose of methylprednisolone was lower for the 
FK 506 patients and the FK 506-converted CyA patients. 
than it was for the Cy A-maintained group. 
Other Adverse Reactions. Both FK 506 and CyA ad-
ministration have been associated with side elfects. many 
of which are similar. The percentages and severity of 
patients experiencing treatment-related adverse reactions 
were recorded. This included evidence of neurotoxicity: 
trembling. paresthesias. Insomnia. Imtability. hyperki-
netic behavior. dysarthria. 5c!lzures. and coma. As can be 
seen in Table 4. the incidence of side effects was essen-
tially the same between both groups. 
CONCLUSIONS 
This trial prOVided a umque opportumtv to compare the 
<:onvenllonal Cy A treatment of liver transplant reCipients 
with a drug t FK 5(6) that IS more potent than Cy A. By 
pert'ormlng a randomized tnal. a more complete determi· 
nation of its advantages and limitations relative to those of 
CyA therapy could be ascertained. From this analysis. It 
appears that FK 506 is at least as effective as Cy A. and 
that. In certain aspects. FK 506 may be superior to CyA. 
Other parameters. such as freedom from rejection. inci-
dence of hypenension. and use of steroids. appear statis-
tlcallv better with FK 506 than with CyA. These benetits 
do not appear to be at the expense of increased incidence 
of renal failure. infectious complicallons. tendency to 
develop diabetes mellitus. or other major side effects. 
The potencv of FK 506 as an ImmunosuppreSSIVe agent 
has been prevlOuslv demonstrated. Both Cy A and FK 506 
bind to a family of cis-tran.f peptldyl prolvl isomerases. S.b 
Charactenzauon of the effect of these agents on mtracel-
lular processes. such as calcium-dependent pathways. and 
the elrect on cytokine expression suggest a differential 
effect by Cy A and FK 506. The relative Similarity of both 
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Table 4. Incidence of Side Effects 
lnadence 
Side E"ect CyA(%) FK 506(%) 
Blurred VISion 13.1 13.2 
Chest pain 2.2 3.7 
Decreased appetite 8.8 9.9 
Diarrhea 12.8 11.7 
Dizziness 5.9 4.6 
Fatigue 8.8 12 
Gas pain 16.3 16.2 
Hair growth 14.1 5.2 
Hair loss 7.5 10.1 
Headache 16.3 23.7 
Hyperesthesia 28.5 21.3 
Musculoskeletal 26.7 20.6 
Increased appetite 7.2 8.3 
Insomnra 28.5 41 
Nausea 6.7 8.3 
Nightmares 2.8 5.0 
PhotophObia 11.7 10.7 
PruritlS 10.7 10.4 
Shortness of breath 5.0 5.5 
Sweating 6.1 7.7 
TInnitus 11.2 6.4 
Tremors 24.0 24.0 
agents on infectious complications probably relates more 
to factors such as the CMY status of the donor and 
recipient as well as to technical complications. rather than 
to an enhanced immunosuppressive quality of either agent. 
In fact. FK 506 has been shown to diminish NK cell 
activity to a less degree than Cy A." The incidence of 
posttransplant I ymphoproliferatlve disease with FK 506 
has been 1.9%. similar to that seen with CyA.'2 
The relative susceptibility of liver transplant recipients 
to nephrotoxicity also relates to penoperatlve nsk factors. 
such as use of nephrotOXIC antibiotics. penoperative hy-
potension. and preexlstln~ renal dysfunction. Tauxe and 
<:oworkers have shown that candidates awaiting liver 
transplantation have a sigmticant preexisting decrement in 
renal function. as manifested by a 35% decrease in esti-
mated renal plasma flow and a 15% decrease in the 
glomerular tiltration rate t privileged communication). Nev-
ertheless. FK 506 and Cy A can affect renal function by 
increasing renal vasoconstriction. perhaps by increasing 
endothelin-I secretion t R. Yatscoff. personal communica-
tionl. The overall cumulative inCidence of renal dysfunc-
tion. manifested by elevation In serum creatinine. has been 
reported in about 70% of all FK 506 liver transplant 
patients. usually dunnll the tirst 2 posttransplant days. IJ 
Both drugs are associated with an increase m the develop-
ment of insulin-dependent diabetes mellitus. by increasing 
the penpheral reSIStance to insulin. and by I.Jimmishing the 
insulin release by islet cells perhaps by inhibition of 
~ynexin-mediated exocytoslS of islet cell granules. 14 
Results of the current randomized study compare favor-
ably to previously reponed results uSing FK 506 and 
I 
FK 506 VS eyA 
therefore do not appear to represent a bias In the perfor-
mance of the study. It is imponant that the resulls of the 
current ongoing randomized trial are comparable to those 
results obtained in the historical senes. The current results 
of patient and graft survival are as good. if not better. than 
those figures obtained in the past. One would expect that 
both graft and patient survival would be better in the 
randomized trial. since the high-risk patients are removed 
from randomization. The randomized FK 506 liver pa-
tients were compared to the survival curves of 271 non-
randomized FK 506 recipients and 813 Cy A recipients 
during the period of time corresponding to the utilization of 
Viaspan (Dupont). The I-year patient survival for the 
high-risk FK 506 liver recipients not entered in the ran-
domized trial approaches 82%. while graft survival is 76%. 
This compares to our historic CyA patient and graft 
survival of 77% and 68%. respectively. The improvement 
of the current randomized Cy A group over the historic 
CyA group mav in pan be related to the abilitv to conven 
patients on CyA to FK 506. 
Ever since the initial enrollment of the ~ I patients 
reponed in this series. a modification of the baseline 
immunosuppression for the CyA limb has been initiated. 
Treatment of the Cy A limb with higher-dose sterOIds and 
inclusion of steroid recycle at the time of transplantation 
and as pan of the treatment of rejection has been imple-
mented. A total of 20 additional Cy A patients have been 
enrolled. The preliminary analysis does not greatly alter 
the findings reponed in this study. The percentage of 
patients who are rejection free using augmented steroids in 
the CyA group is 237c at 6 months. while the correspond-
ing Incidence for FK 5Q6..treated patients IS ~K;% at the 
,ame period. although the percentage of pallents who have 
heen convened from (y A to FK 506 IS lower at 54l7r. 
2983 
Ongoing prospective randomized trials of Cy A vs FK 
~MS for primary liver transplantation are also underway in 
multicenter trials in the United States and in Europe. More 
,tringent criteria for conversion of Cy A-treated patients to 
FK 506 will allow one to evaluate the impact of Cy A and 
FK 506 immunosuppression on primary endpoints includ-
ing patient and graft survival. 
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